Rem Sleep Behavior Disorder (Rbd) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
REM Sleep Behavior Disorder (RBD) is a parasomnia characterized by the loss of normal skeletal muscle atonia during rapid eye movement (REM) sleep, resulting in dream-enactment behaviors that can range from simple limb movements to violent thrashing, punching, and kicking. First described by Carlos Schenck and Mark Mahowald in 1986, RBD has emerged as one of the most important prodromal markers of [alpha-synucleinopathies[/diseases/[alpha-synucleinopathies[/diseases/[alpha-synucleinopathies[/diseases/[alpha-synucleinopathies--TEMP--/diseases)--FIX--, including [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX--, and [multiple system atrophy[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX--.
The prevalence of RBD in the general population is estimated at 0.5–2%, with higher rates in men and older adults. However, the clinical significance of RBD extends far beyond its sleep-related symptoms: longitudinal studies have established that more than 80% of individuals with isolated RBD (iRBD)—those without an overt neurodegenerative diagnosis—will eventually develop a full synucleinopathy, with annual phenoconversion rates of 6–8%. This remarkable predictive power has made RBD a critical focus for neuroprotective trial design, early biomarker development, and disease-modifying intervention research.
During normal REM sleep, descending pathways from the [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX-- actively inhibit spinal motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- through a combination of glycinergic and GABAergic mechanisms. The key structures involved include:
- Sublaterodorsal nucleus (SLD): The pontine REM sleep-generating center that sends glutamatergic projections to the ventromedial medulla.
- Ventromedial medulla (VMM): Relays inhibitory signals (glycine and [GABA) to spinal motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, producing the atonia characteristic of REM sleep.
- Pedunculopontine nucleus (PPN): Cholinergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- that modulate REM sleep transitions.
In RBD, neurodegeneration or dysfunction of the brainstem circuits that generate REM atonia leads to incomplete or absent muscle paralysis during REM sleep. The pathological process involves:
- [alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX-- deposition: [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- aggregates accumulate in brainstem nuclei controlling REM sleep, including the SLD, [locus coeruleus[/brain-regions/[locus-coeruleus[/brain-regions/[locus-coeruleus[/brain-regions/[locus-coeruleus--TEMP--/brain-regions)--FIX--, and dorsal raphe nucleus.
- Neuronal loss: Progressive loss of REM-atonia generating [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in the SLD and surrounding regions.
- Circuit disruption: Impaired glycinergic/GABAergic inhibition of spinal motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- during REM sleep.
This aligns with the [Braak staging[/mechanisms/[braak-staging[/mechanisms/[braak-staging[/mechanisms/[braak-staging--TEMP--/mechanisms)--FIX-- model of [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, where alpha begins in the lower brainstem and olfactory bulb (Braak stages 1–2) before ascending to the [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX-- (stage 3) and [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- (stages 4–6). RBD corresponds to Braak stages 1–2, explaining why it often precedes motor symptoms by years to decades.
The neurodegenerative process that causes RBD simultaneously affects autonomic brainstem nuclei and peripheral autonomic structures, explaining the frequent co-occurrence of autonomic dysfunction:
- Cardiac sympathetic denervation: Reduced cardiac 123I-MIBG uptake, reflecting loss of postganglionic sympathetic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--.
- Olfactory dysfunction: Reduced sense of smell, reflecting olfactory bulb pathology.
- Constipation: Reflecting enteric nervous system alpha and the [Gut-Brain Axis[/entities/[gut-brain-axis[/entities/[gut-brain-axis[/entities/[gut-brain-axis--TEMP--/entities)--FIX-- connection.
- Orthostatic hypotension: Impaired baroreflex function.
The hallmark of RBD is the acting out of dreams during REM sleep:
- Mild: Talking, laughing, shouting, or singing during sleep; limb jerks and twitches.
- Moderate: Reaching, grabbing, gesturing, or arm/leg movements corresponding to dream content.
- Severe: Punching, kicking, leaping from bed, or complex violent motor behaviors. Can result in significant injury to the patient or bed partner.
Dream content in RBD is characteristically vivid and often involves themes of being chased, attacked, or defending against an aggressor—distinct from the patient's waking personality.
Individuals with iRBD frequently exhibit subtle prodromal features of synucleinopathy years before phenoconversion:
- Hyposmia: Present in 40–60% of iRBD patients; reflects early olfactory pathology.
- Constipation: Reported in 40–50%; may precede RBD diagnosis.
- Depression and anxiety: Present in 20–40%, reflecting [serotonergic] and [noradrenergic] brainstem pathology.
- Subtle motor signs: Reduced arm swing, mild rigidity, and slowed gait detectable before clinical parkinsonism.
- Cognitive changes: Subtle executive and visuospatial deficits, detectable on neuropsychological testing.
- Color vision changes: Impaired color discrimination reflecting retinal or visual pathway involvement.
- Daytime sleepiness: Excessive daytime somnolence.
The definitive diagnosis of RBD requires video polysomnography (vPSG) demonstrating:
- REM sleep without atonia (RSWA): Excessive sustained or intermittent elevation of submental EMG tone during REM sleep, or excessive phasic EMG activity in the chin or limb muscles.
- Documented dream-enactment behaviors: Observed during the recording or documented by clinical history.
The International Classification of Sleep Disorders, 3rd edition (ICSD-3) established a quantitative cutoff of >27% of REM sleep epochs containing tonic or phasic muscle activity for the EMG criterion.
When polysomnography is not available, probable RBD can be diagnosed based on:
- Clinical history of recurrent dream-enactment behavior.
- Bed partner report of movements during sleep.
- Exclusion of other causes (obstructive sleep apnea, nocturnal seizures, sleepwalking).
- RBD Screening Questionnaire (RBDSQ): 13-item self-report questionnaire; score >=5 suggests RBD.
- RBD Single-Question Screen (RBD1Q): "Have you ever been told, or suspected yourself, that you seem to act out your dreams while asleep?"
- Mayo Sleep Questionnaire: Validated bedpartner-informant questionnaire.
- Isolated RBD (iRBD): No current neurodegenerative or other identifiable cause. This is the prodromal synucleinopathy phenotype.
- Secondary RBD: Occurring in the context of established [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX--, [MSA[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX--, narcolepsy, [autoimmune encephalitis[/diseases/[autoimmune-encephalitis[/diseases/[autoimmune-encephalitis[/diseases/[autoimmune-encephalitis--TEMP--/diseases)--FIX--, brainstem lesions, or medication use (antidepressants, particularly SSRIs and SNRIs).
¶ Rates and Timeline
The natural history of iRBD has been extensively studied in multicenter longitudinal cohorts:
- Annual conversion rate: 6–8% per year.
- 5-year cumulative rate: ~35–41% develop overt neurodegenerative disease.
- 8-year cumulative rate: ~50%.
- 12-year cumulative rate: ~75%.
- Lifetime risk: >90% (estimated from extended follow-up studies).
Among individuals with iRBD who phenoconvert:
- [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--: ~45–50% of conversions.
- [Dementia with Lewy Bodies (DLB)[/diseases/[dementia-lewy-bodies[/diseases/[dementia-lewy-bodies[/diseases/[dementia-lewy-bodies--TEMP--/diseases)--FIX--: ~25–35% of conversions.
- [Multiple System Atrophy (MSA)[/diseases/[multiple-system-atrophy[/diseases/[multiple-system-atrophy[/diseases/[multiple-system-atrophy--TEMP--/diseases)--FIX--: ~5–10% of conversions.
- [Mild Cognitive Impairment[/diseases/[mci[/diseases/[mci[/diseases/[mci--TEMP--/diseases)--FIX--: ~10–15% develop MCI as an intermediate stage before full dementia.
Research has identified several biomarkers that predict the timing and type of phenoconversion:
- Quantitative motor testing: Subtle parkinsonian signs (bradykinesia, rigidity) predict faster conversion.
- Cognitive testing: Impaired visuospatial and attentional performance predicts conversion to DLB.
- Olfactory testing: Severe hyposmia predicts shorter time to phenoconversion.
- Autonomic testing: Orthostatic hypotension and cardiac denervation predict faster conversion.
- [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- transporter (DAT) imaging: Reduced striatal DAT binding (DaTSCAN) is present in ~40% of iRBD patients and predicts conversion within 3–5 years.
- MRI: Volumetric changes in [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX--, [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX--, and [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--.
- FDG-PET: Metabolic patterns resembling early PD or DLB.
- Connectomics: Altered brain network connectivity predicts phenoconversion trajectory.
- alpha-synuclein seed amplification assay (SAA): CSF [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- SAA is positive in >90% of iRBD patients, confirming the synucleinopathy nature of iRBD.
- [Neurofilament light chain ([NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--: Elevated levels predict faster progression.
- [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX--: Elevated glial fibrillary acidic protein may reflect early [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- reactivity.
- [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX--: Helps exclude AD co-pathology.
- EEG slowing: Background EEG slowing during wakefulness predicts cognitive phenoconversion.
- Event-related potentials (ERPs): Altered cue-elicited ERPs during visuospatial attention tasks predict phenoconversion.
- Mechanism: Enhances [GABA-A] receptor activity, reducing phasic muscle activity during REM sleep.
- Dose: 0.25–2 mg at bedtime.
- Efficacy: Widely used first-line agent; reduces dream-enactment behaviors in ~80–90% of patients based on clinical experience. However, recent randomized controlled trials have not demonstrated superiority over placebo.
- Cautions: Risk of falls (especially in elderly), daytime sedation, worsening of obstructive sleep apnea, cognitive effects.
- Mechanism: Modulates REM sleep regulation; may restore REM atonia through effects on brainstem circuits.
- Dose: 3–12 mg at bedtime (higher doses typically needed for RBD).
- Efficacy: Considered first-line in patients with contraindications to clonazepam. May be particularly effective in reducing REM sleep without atonia on polysomnography. Impacts sleep architecture with increased N3 and increased REM latency.
- Advantages: Fewer side effects than clonazepam; no risk of dependency; may be neuroprotective.
Essential non-pharmacological interventions include:
- Padding the bedroom floor.
- Removing sharp or breakable objects from the bedside.
- Placing the mattress on the floor.
- Sleeping in separate beds if bed partner injury occurs.
- Bed rails with padding.
The recognition of iRBD as a prodromal synucleinopathy has catalyzed efforts to develop neuroprotective interventions:
- Anti-[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- immunotherapy: Antibodies targeting alpha and [prion-like spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading--TEMP--/mechanisms)--FIX--.
- [GLP-1 receptor agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists[/treatments/[glp1-receptor-agonists--TEMP--/treatments)--FIX--: Semaglutide and exenatide under investigation for neuroprotective effects in iRBD cohorts.
- Exercise interventions: High-intensity aerobic exercise trials in iRBD populations.
- Iron chelation: Targeting iron accumulation in the [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX--.
- Primary outcome: Phenoconversion to clinically defined synucleinopathy (PD, DLB, MSA) is the gold-standard outcome, but requires large samples and long follow-up (5+ years).
- Biomarker endpoints: DAT imaging, [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- SAA, and [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- levels are being validated as surrogate endpoints.
- Enrichment strategies: Selecting high-risk iRBD patients (DAT-positive, cognitive decline) can improve trial efficiency.
- Ethical considerations: Communicating risk of neurodegeneration to iRBD patients while avoiding undue distress.
¶ Epidemiology and Risk Factors
- Sex: Male predominance (60–80% of cases), though this may partly reflect ascertainment bias and bed partner reporting.
- Age: Median age of onset 60–70 years, though can occur at any age.
- Race/ethnicity: Less well-studied; preliminary data suggest similar prevalence across populations.
- Antidepressant use: SSRIs, SNRIs, and tricyclic antidepressants can unmask or exacerbate RBD.
- Post-traumatic stress disorder: PTSD-associated RBD may represent a distinct, non-neurodegenerative subtype.
- Narcolepsy: RBD occurs in ~35–60% of narcolepsy patients but typically does not predict synucleinopathy.
- Pesticide exposure: Epidemiological association with parkinsonism risk factors.
- Head trauma: History of [traumatic brain injury[/diseases/[traumatic-brain-injury[/diseases/[traumatic-brain-injury[/diseases/[traumatic-brain-injury--TEMP--/diseases)--FIX-- may increase risk.
- [GBA1[/genes/[gba[/genes/[gba[/genes/[gba--TEMP--/genes)--FIX-- variants: Glucocerebrosidase mutations, the strongest genetic risk factor for PD, are enriched in iRBD cohorts.
- [LRRK2[/genes/[lrrk2[/genes/[lrrk2[/genes/[lrrk2--TEMP--/genes)--FIX-- mutations: Paradoxically, LRRK2-associated PD has a lower rate of RBD compared to idiopathic PD.
- **[APOE[/entities/apoehttps://doi.org/10.1093/sleep/9.2.[293[/entities/apoehttps://doi.org/10.1093/sleep/9.2.[293[/entities/apoehttps://doi.org/10.1093/sleep/9.2.[293--TEMP--/entities/apoehttps://doi.org/10.1093)--FIX--
- [Postuma RB, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019;142(3):744-759. DOI
- [Iranzo A, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013;12(5):443-453. DOI
- [Hogl B, et al. Idiopathic REM sleep behaviour disorder and neurodegeneration: an update. Nat Rev Neurol. 2018;14(1):40-55. DOI
- [St Louis EK, Boeve BF. REM sleep behavior disorder: diagnosis, clinical implications, and future directions. Mayo Clin Proc. 2017;92(11):1723-1736. DOI
- [Miglis MG, et al. Biomarkers of conversion to alpha-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol. 2021;20(8):671-684. DOI
- [Galbiati A, et al. REM sleep behavior disorder as a prodromal synucleinopathy: updates on clinical and laboratory biomarkers, and implications for neuroprotective trials. Curr Neurol Neurosci Rep. 2025;25:15. DOI
- [Cesari M, et al. Polysomnographic features associated with clonazepam and melatonin treatment in isolated REM sleep behavior disorder. Sleep Med. 2024;115:14-21. DOI
- [Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19(4):591-596. DOI
- [Postuma RB, et al. Neuroprotective trials in REM sleep behavior disorder. Neurology. 2022;99(1 Suppl 1):S26-S35. DOI
- [Stefani A, Hogl B. Diagnostic criteria, differential diagnosis, and treatment of minor motor activity and less well-known movement disorders of sleep. Curr Treat Options Neurol. 2019;21(1):1. DOI
- [Dauvilliers Y, et al. REM sleep behaviour disorder. Nat Rev Dis Primers. 2018;4(1):19. DOI
The study of Rem Sleep Behavior Disorder (Rbd) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [/diseases/alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--
- [/mechanisms/amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis--TEMP--/mechanisms)--FIX--
- [/mechanisms/tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology--TEMP--/mechanisms)--FIX--
- [/diseases/parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--
- [/mechanisms/alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX--
- [Postuma RB, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019;142(3):744-759. DOI
- [Iranzo A, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013;12(5):443-453. DOI
- [Hogl B, et al. Idiopathic REM sleep behaviour disorder and neurodegeneration: an update. Nat Rev Neurol. 2018;14(1):40-55. DOI
- [St Louis EK, Boeve BF. REM sleep behavior disorder: diagnosis, clinical implications, and future directions. Mayo Clin Proc. 2017;92(11):1723-1736. DOI
- [Miglis MG, et al. Biomarkers of conversion to alpha-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol. 2021;20(8):671-684. DOI
- [Galbiati A, et al. REM sleep behavior disorder as a prodromal synucleinopathy: updates on clinical and laboratory biomarkers, and implications for neuroprotective trials. Curr Neurol Neurosci Rep. 2025;25:15. DOI
- [Cesari M, et al. Polysomnographic features associated with clonazepam and melatonin treatment in isolated REM sleep behavior disorder. Sleep Med. 2024;115:14-21. DOI
- [Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19(4):591-596. DOI
- [Postuma RB, et al. Neuroprotective trials in REM sleep behavior disorder. Neurology. 2022;99(1 Suppl 1]:S26-S35. DOI
- [Stefani A, Hogl B. Diagnostic criteria, differential diagnosis, and treatment of minor motor activity and less well-known movement disorders of sleep. Curr Treat Options Neurol. 2019;21(1):1. DOI
- [Dauvilliers Y, et al. REM sleep behaviour disorder. Nat Rev Dis Primers. 2018;4(1):19. DOI## See Also
-
- [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- — Most common synucleinopathy following RBD
-
- [Dementia with Lewy Bodies[/diseases/[dementia-lewy-bodies[/diseases/[dementia-lewy-bodies[/diseases/[dementia-lewy-bodies--TEMP--/diseases)--FIX-- — Synucleinopathy with RBD as prodromal symptom
-
- [multiple system atrophy[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX-- — Another synucleinopathy linked to RBD
-
- [alpha-synuclein Aggregation] — Pathological process underlying RBD phenoconversion
-
- [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX-- — Region where RBD pathology originates